Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-201 in FGFR-altered metastatic or unresectable urothelial carcinoma
NL-OMON49349Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemigatinib in transitional cell carcinoma (TCC) and bladder cancer (3 cohorts), sponsored by Incyte. Primary endpoint: Objective response rate. Started Jan 2017; status: active, not recruiting.
02
Drugs
pemigatinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON49349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49349.